Pharmaceutical import into Germany is governed by a precise regulatory framework that creates both obligations and opportunities for international traders. Whether you are pursuing parallel import, individual import under Article 73.3 AMG, or exploring niche products delisted from the German market, every import pathway requires structured data: authorization status in the source country, pricing differentials, shortage signals, and regulatory equivalence documentation. This guide explains the three main import routes into Germany, the data and compliance requirements for each, and how specialized pharmaceutical databases can systematically support your sourcing and regulatory workflow.

The German Medicinal Products Act (Arzneimittelgesetz, AMG) defines the legal framework for importing pharmaceutical products. Three distinct pathways exist, each with different prerequisites, authorization procedures, and commercial implications. Understanding which pathway applies to a given product is the first strategic decision in any import operation.

Parallel Import under §73 Abs. 1 AMG

Parallel import is the commercial-scale importation of a medicinal product that holds a valid marketing authorization in both the source EEA country and in Germany. The imported product must be essentially similar to the German reference product in terms of active substance, strength, and pharmaceutical form. The importer must obtain a parallel import license (Parallelimportgenehmigung) from the BfArM (Federal Institute for Drugs and Medical Devices).

Key requirements for parallel import include:

• Valid marketing authorization in the source EEA member state
• Corresponding German marketing authorization for the reference product
• BfArM parallel import license confirming essential similarity
• Repackaging or relabeling to meet German labeling requirements (German-language package leaflet, German PZN assignment)
• Price advantage meeting the tiered thresholds under the Framework Agreement (Rahmenvertrag, §129 SGB V): at least 15% below the reference product price for products up to EUR 100, at least EUR 15 for products between EUR 100 and EUR 300, and at least 5% for products above EUR 300
• GDP-compliant supply chain from source country to German wholesaler or pharmacy

Parallel import remains the largest volume pathway in Europe. Germany is the single largest market for pharmaceutical parallel trade, accounting for more than half of the estimated EUR 5.5 billion EU-wide parallel import market. German pharmacies are also required to meet an import quota of 2% of their dispensing volume per health fund and quarter (§129 SGB V). The business model depends entirely on parallel import pharma Germany data — specifically, the ability to identify products where the price differential between source and target market exceeds the cost of repackaging, regulatory compliance, and logistics.

Individual Import under §73 Abs. 3 AMG (Article 73.3 AMG Import Guide)

§73 Abs. 3 AMG is the legal basis for importing medicinal products that are not authorized in Germany. This pathway allows German pharmacies to procure a product from abroad on the basis of an individual physician’s prescription when no equivalent authorized product is available or accessible in Germany. The Article 73.3 AMG import guide can be summarized in three conditions:

1. The product is lawfully placed on the market in the country of origin
2. No comparable authorized product is available in Germany, or the authorized product is currently unavailable (e.g., due to a supply shortage)
3. An individual prescription from a treating physician exists for a specific patient

This pathway has gained substantial practical relevance due to persistent drug shortages. The BfArM shortage database listed 562 active entries as of March 2026, up from 487 in late 2024 — reflecting a persistent upward trend. Each shortage can trigger legitimate import demand under §73 Abs. 3 AMG, creating a direct link between Germany drug shortage import opportunity signals and commercial import activity.

Centralized EU Authorization (EMA)

Products authorized through the European Medicines Agency (EMA) under the centralized procedure hold a single marketing authorization valid in all EU/EEA member states simultaneously. These products do not require a separate national import license for Germany, as the authorization already covers the German market. However, distribution still requires GDP compliance, FMD verification, and a valid wholesale distribution authorization (Grosshandelserlaubnis) in Germany.

Data Requirements for Pharmaceutical Import into Germany

Every import pathway demands structured, current data at multiple stages — from opportunity identification through regulatory filing to ongoing compliance. The following table maps the critical data points to each import stage.

The central challenge for importers is data fragmentation. Authorization data sits with 26+ national medicines agencies. Pricing data is maintained by national health insurance systems. Shortage information is published by individual competent authorities (BfArM in Germany, AIFA in Italy, AEMPS in Spain). Assembling a complete picture for a single product across five source countries can require consulting ten or more separate databases manually. In a market where Germany alone has approximately 18,000 pharmacies served by nine full-line wholesalers (organized under PHAGRO) operating from 106 branches, the demand for reliable import data infrastructure is substantial.

How pharmazie.com Supports Pharmaceutical Importers

pharmazie.com is a consolidated pharmaceutical data platform covering 50+ countries and 25+ databases in a single search interface. For pharmaceutical importers, parallel traders, and regulatory affairs professionals, the platform provides the data infrastructure that import operations require at every stage. The platform contains the ABDA-Artikelstamm for German product data and offers international coverage that is particularly relevant for cross-border sourcing.

Eisbergsuche: Parallel Search Across 25+ Databases

The Eisbergsuche (Iceberg Search) is the core search function of pharmazie.com. Instead of querying national databases one by one, importers enter a single search term — an active ingredient, a brand name, an ATC code — and receive consolidated results from all connected databases simultaneously. This eliminates the manual process of checking multiple national registers and immediately reveals which markets carry a given product.

International Database Covering 50+ Countries

The platform aggregates authorization and product data from over 50 countries, including all major EU/EEA markets. For each product, importers can see:

• Marketing authorization status and authorization holder in the source country
• Available strengths, pack sizes, and pharmaceutical forms
• ATC classification and active substance identification
• Whether the product is currently marketed or has been withdrawn

This international coverage is essential for identifying niche hospital medicine sourcing in Europe and for building a pipeline of import candidates across multiple source markets.

Drug Shortage Database: Identifying Import Opportunities

The pharmazie.com shortage database is updated daily and covers all officially reported supply shortages in Germany. Each shortage entry is enriched with information about alternative products available in other EU member states. This direct linkage between a German shortage and available alternatives abroad is precisely the data signal that triggers a legitimate §73 Abs. 3 AMG import. Importers can monitor new shortage alerts continuously and act on emerging opportunities before competitors.

PZN-to-EU Authorization Number Mapping

One of the most time-consuming tasks in parallel import applications is establishing the link between a German PZN (Pharmazentralnummer) and the corresponding authorization numbers in source countries. pharmazie.com maintains cross-references between German product identifiers and international authorization data, reducing the manual research effort required for BfArM parallel import applications.

International Price Comparison

Profitable parallel import depends on price differentials. The platform provides pricing data across multiple markets, allowing importers to identify products where the spread between the source country ex-factory price and the German reference price is sufficient to cover repackaging, logistics, and regulatory costs while meeting the tiered price-gap thresholds required under §129 SGB V.

Discontinued Drugs Archive

Products that have been delisted in Germany but remain authorized in other EU markets represent a specific niche opportunity. The pharmazie.com pharmaceutical product lifecycle database archives every product deletion from the German market, including the deletion date, original composition, and authorization history. This discontinued drugs Germany archive allows importers and niche pharma companies to identify products where clinical demand may persist despite market withdrawal — the starting point for well-established use filings or re-import strategies.

API and Data Export

For importers who need to integrate pharmaceutical data into their own systems — ERP, warehouse management, or regulatory tracking tools — pharmazie.com offers a REST API and data export in CSV, JSON, and XML formats. Automated data feeds ensure that pricing changes, new shortage alerts, and product lifecycle events are reflected in the importer’s systems without manual intervention.

GDP Compliance and FMD Serialization for Importers

Good Distribution Practice (GDP) is a mandatory quality standard for all entities involved in the pharmaceutical supply chain, including importers. Compliance with the EU GDP Guidelines (2013/C 343/01) is a prerequisite for obtaining and maintaining a wholesale distribution authorization in Germany.

Key GDP requirements relevant to pharmaceutical importers include:

• Qualified Person (Responsible Person): Every wholesale distributor must designate a qualified person responsible for ensuring GDP compliance across all operations
• Temperature-controlled logistics: Documented cold chain management for temperature-sensitive products, including validated shipping containers and continuous temperature monitoring
• Supplier qualification: Verification that all upstream suppliers hold valid GDP certificates and wholesale distribution authorizations
• Traceability: Complete batch-level traceability from source to destination, enabling rapid recall execution if required
• Self-inspections: Regular internal audits against GDP standards, documented with corrective actions

FMD Serialization Requirements

The EU Falsified Medicines Directive (FMD, 2011/62/EU) requires that prescription medicines carry a unique identifier (serialization) and an anti-tampering device. For parallel importers, this creates specific obligations:

• Decommissioning and recommissioning: When repackaging a product, the original serialization must be decommissioned in the source country’s national verification system, and a new German serial number must be applied and uploaded to securPharm (the German verification system)
• Anti-tampering device replacement: The original tamper-evident seal must be replaced with a new one during repackaging
• End-to-end verification: German pharmacies verify every prescription product against securPharm at the point of dispensing — any discrepancy blocks the sale

For §73 Abs. 3 AMG individual imports, FMD verification follows a different process. The dispensing pharmacy verifies the product against the source country’s verification system, or uses the EU Hub as a fallback. This process is less standardized and often requires manual coordination between the importing pharmacy and the source country’s national medicines verification organization.

Practical Checklist: Starting a Pharmaceutical Import Operation in Germany

Establishing a pharmaceutical import business in Germany requires parallel workstreams in regulatory, operational, and commercial preparation. The following checklist covers the essential steps.

1. Obtain a wholesale distribution authorization (Grosshandelserlaubnis) from the competent state authority (Landesbehorde). This requires documented GDP compliance, qualified personnel, and appropriate warehouse facilities.
2. Designate a Qualified Person with the required pharmaceutical qualifications and experience in GDP-compliant operations.
3. Establish GDP-compliant warehouse and logistics infrastructure including temperature mapping, pest control, security systems, and documentation procedures.
4. Set up supplier qualification processes to verify GDP certificates, wholesale licenses, and product authenticity for every source supplier.
5. Register with securPharm for FMD serialization compliance if handling prescription medicines.
6. Build your product pipeline using data tools. Use a pharmaceutical product lifecycle database like pharmazie.com to identify products with favorable price differentials, active shortage signals, or discontinuation-driven demand.
7. Apply for parallel import licenses at BfArM for each product you intend to import commercially. Prepare SmPC comparisons, authorization documentation from the source country, and proposed German labeling.
8. Establish relationships with German wholesalers and pharmacies as distribution channels for your imported products.

Niche Opportunities: Where Data Makes the Difference

The most profitable import opportunities often sit in niches that larger traders overlook. Three categories of niche pharmaceutical opportunities in Europe are systematically identifiable through structured data analysis:

Drug shortages with EU alternatives. When a product enters shortage status in Germany, pharmacies actively seek alternatives. If the same product or a therapeutically equivalent alternative is available in another EU market, the §73 Abs. 3 AMG pathway opens. The speed of identifying and acting on these signals determines who captures the opportunity. A daily-updated shortage database with automatic cross-referencing to drug availability in Europe by country provides a decisive advantage.

Delisted products with persistent demand. A drug delisted in Germany but authorized in the EU elsewhere represents a gap in the market. Hospital pharmacies and specialists who previously prescribed the product still need it. The importer who can identify these products, confirm ongoing authorization in a source market, and supply them under §73 Abs. 3 AMG fills a clinical need and creates a recurring revenue stream.

Well-established use candidates. Products with more than ten years of documented medical use in the EU can be registered through the well-established use pathway under Article 10a of Directive 2001/83/EC. This pathway allows applicants to substitute clinical trial data with published literature, significantly reducing the cost and time of obtaining a marketing authorization. Identifying candidates requires historical authorization data — exactly the type of information maintained in a discontinued drugs Germany archive.

Conclusion: Data Infrastructure as a Competitive Advantage in Pharmaceutical Import

Pharmaceutical import into Germany is a data-intensive operation from start to finish. The regulatory framework — whether parallel import under §73 Abs. 1 AMG, individual import under §73 Abs. 3 AMG, or centralized EU authorization — defines specific data requirements at every stage. Importers who rely on manual research across fragmented national databases lose time and miss opportunities. Those who invest in consolidated data infrastructure — international authorization databases, real-time shortage monitoring, pricing comparisons, and product lifecycle archives — operate faster and more profitably. pharmazie.com provides this infrastructure, covering 50+ countries in a single platform with the Eisbergsuche, API access, and specialized modules for shortage monitoring and discontinued product analysis.

Frequently Asked Questions

What is §73 Abs. 3 AMG and when does it apply?

§73 Abs. 3 AMG is the provision in the German Medicinal Products Act that permits the import of pharmaceutical products not authorized in Germany. It applies when a physician prescribes a specific product for an individual patient and no comparable authorized product is available on the German market — either because no equivalent exists or because the authorized product is currently subject to a supply shortage. The importing pharmacy must verify that the product is lawfully marketed in its country of origin.

What is the difference between parallel import and individual import of pharmaceuticals in Germany?

Parallel import (§73 Abs. 1 AMG) involves commercial-scale importation of products that hold marketing authorizations in both the source country and Germany. It requires a BfArM parallel import license, repackaging with German labeling, and meeting tiered price-gap thresholds under §129 SGB V. Individual import (§73 Abs. 3 AMG) covers products not authorized in Germany, operates on a per-patient prescription basis, and does not require a BfArM import license. Parallel import is a commercial model; individual import is a patient-need-driven exception.

How can pharmazie.com help identify pharmaceutical import opportunities?

pharmazie.com consolidates pharmaceutical data from 50+ countries into a single searchable platform. Importers use the Eisbergsuche to find products across all connected databases simultaneously, the daily-updated shortage database to identify §73 Abs. 3 AMG import triggers, the international price comparison to calculate parallel import margins, and the discontinued drugs archive to find niche re-import candidates. Data exports via API (CSV, JSON, XML) allow integration into the importer’s own ERP and tracking systems.

What GDP requirements must pharmaceutical importers in Germany meet?

All pharmaceutical importers operating in Germany must hold a wholesale distribution authorization (Grosshandelserlaubnis) and comply with EU Good Distribution Practice guidelines (2013/C 343/01). Key requirements include designating a Qualified Person, maintaining temperature-controlled storage and transport, qualifying all suppliers through documented audits, ensuring full batch-level traceability, and conducting regular self-inspections. For prescription medicines, registration with the German securPharm system for FMD serialization verification is also mandatory.

Can I import a drug that has been discontinued in Germany but is still authorized elsewhere in the EU?

Yes. If a product has been delisted from the German market for commercial reasons (not safety withdrawal) and remains authorized in another EU/EEA member state, it can be imported into Germany under §73 Abs. 3 AMG on an individual prescription basis. Alternatively, if the product has sufficient documented use history (ten years or more), a new marketing authorization can be pursued through the well-established use pathway under Directive 2001/83/EC, Article 10a. pharmazie.com maintains a comprehensive archive of discontinued German products with cross-references to ongoing authorizations in other countries, making it possible to identify these opportunities systematically.